These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30817231)

  • 1. Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials.
    Kornbrust D
    Nucleic Acid Ther; 2019 Jun; 29(3):123-125. PubMed ID: 30817231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An FDA oncology analysis of antibody-drug conjugates.
    Saber H; Leighton JK
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):444-52. PubMed ID: 25661711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical warfare agents: estimating oral reference doses.
    Opresko DM; Young RA; Faust RA; Talmage SS; Watson AP; Ross RH; Davidson KA; King J
    Rev Environ Contam Toxicol; 1998; 156():1-183. PubMed ID: 9597943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
    Bokkers BG; Slob W
    Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating dosages from animal models to human clinical trials--revisiting body surface area scaling.
    Blanchard OL; Smoliga JM
    FASEB J; 2015 May; 29(5):1629-34. PubMed ID: 25657112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies.
    Baldrick P; Reichl A
    Regul Toxicol Pharmacol; 2021 Apr; 121():104869. PubMed ID: 33482290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose.
    Jessen BA; Cornwell P; Redmond S; Visalli T; Lemper M; Bunch T; Hart T
    Cancer Chemother Pharmacol; 2023 Dec; 92(6):455-464. PubMed ID: 37505272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allometric principles for interspecies extrapolation in toxicological risk assessment--empirical investigations.
    Schneider K; Oltmanns J; Hassauer M
    Regul Toxicol Pharmacol; 2004 Jun; 39(3):334-47. PubMed ID: 15135212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derivation of a bisphenol A oral reference dose (RfD) and drinking-water equivalent concentration.
    Willhite CC; Ball GL; McLellan CJ
    J Toxicol Environ Health B Crit Rev; 2008 Feb; 11(2):69-146. PubMed ID: 18188738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo Hypoglycemic Studies of Polyherbal Phytoceuticals, Their Pharmacokinetic Studies and Dose Extrapolation by Allometric Scaling.
    De B; Bhandari K; Katakam P; Mitra A
    Curr Drug Discov Technol; 2017; 14(4):277-292. PubMed ID: 28359233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management.
    Dambach DM; Simpson NE; Jones TW; Brennan RJ; Pazdur R; Palmby TR
    Clin Cancer Res; 2016 Jun; 22(11):2618-22. PubMed ID: 27250932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose translation from animal to human studies revisited.
    Reagan-Shaw S; Nihal M; Ahmad N
    FASEB J; 2008 Mar; 22(3):659-61. PubMed ID: 17942826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment.
    Tessier Y; Achanzar W; Mihalcik L; Amuzie C; Andersson P; Parry JD; Moggs J; Whiteley LO
    Nucleic Acid Ther; 2021 Feb; 31(1):7-20. PubMed ID: 33054599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Silico Models for Repeated-Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for Drugs.
    Pizzo F; Benfenati E
    Methods Mol Biol; 2016; 1425():163-76. PubMed ID: 27311467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hazard characterisation of chemicals in food and diet. dose response, mechanisms and extrapolation issues.
    Dybing E; Doe J; Groten J; Kleiner J; O'Brien J; Renwick AG; Schlatter J; Steinberg P; Tritscher A; Walker R; Younes M
    Food Chem Toxicol; 2002; 40(2-3):237-82. PubMed ID: 11893399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial allometric factor extrapolation: compartmental and physiological pharmacokinetic approaches.
    Hill TA; Wands RC
    Health Phys; 1989; 57 Suppl 1():395-401. PubMed ID: 2514157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICH S9: Developing anticancer drugs, one year later.
    Ponce R
    Toxicol Pathol; 2011 Oct; 39(6):913-5. PubMed ID: 21859887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interspecific scaling of toxicity data.
    Travis CC; White RK
    Risk Anal; 1988 Mar; 8(1):119-25. PubMed ID: 3375501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
    Felici A; Verweij J; Sparreboom A
    Eur J Cancer; 2002 Sep; 38(13):1677-84. PubMed ID: 12175683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.